Pediatr. praxi. 2023;24(2):116-119 | DOI: 10.36290/ped.2023.034

Hypertension not treatable with enalapril in a boy with recurrent acute myocarditis

MUDr. Simona Ulrich1, MUDr. Eva Drahokoupilová1, MUDr. David Sumerauer, Ph.D.1, MUDr. Patrik Konopásek2, MUDr. Lucie Slámová, Ph.D.1, doc. MUDr. Lucie ©rámková, Ph.D.1
1 Klinika dětské hematologie a onkologie, 2. LF UK a FN Motol, Praha
2 Pediatrická klinika, 2. LF UK a FN Motol, Praha

Secondary hypertension in the paediatric preadolescent population prevails over primary hypertension. Although in most children, the cause is renal or cardiac, it is also necessary to consider endocrine and other factors. Here we present the case report of an 11-year-old boy, who presented predominantly with signs of acute myocarditis, and the cause of hypertension was clarified only at the second attack of these problems. A tumour was found in the retroperitoneum by ultrasound, later histologically determined to be a paraganglioma. Endogenous overproduction of catecholamines based on the presence of paraganglioma represents a very rare cause of hypertension not only in children. The biological behaviour of this tumour is malignant in 10% of patients, especially if there is a hereditary predisposition. Therefore, early detection and complex treatment of the disease are essential.

Keywords: secondary hypertension, paraganglioma, genetic predisposition.

Accepted: March 31, 2023; Published: April 5, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ulrich S, Drahokoupilová E, Sumerauer D, Konopásek P, Slámová L, ©rámková L. Hypertension not treatable with enalapril in a boy with recurrent acute myocarditis. Pediatr. praxi. 2023;24(2):116-119. doi: 10.36290/ped.2023.034.
Download citation

References

  1. Bouhanick B, Sosner P, Brochard K, et al. Hypertension in Children and Adolescents: A Position Statement From a Panel of Multidisciplinary Experts Coordinated by the French Society of Hypertension. Front Pediatr. 2021;9:680803. Go to original source... Go to PubMed...
  2. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3). Go to original source...
  3. Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. Am J Hypertens. 2015;28(1):73-80. Go to original source...
  4. Law YM, Lal AK, Chen S, et al. Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association. Circulation. 2021;144(6):e123-135. Go to original source...
  5. Pomiato E, Perrone MA, Palmieri R, et al. Pediatric Myocarditis: What Have We Learnt So Far? J Cardiovasc Dev Dis. 2022;9(5). Go to original source... Go to PubMed...
  6. Santos JRU, Brofferio A, Viana B, et al. Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease? Horm Metab Res. 2019;51(7):458-469. Go to original source...
  7. Kassim TA, Clarke DD, Mai VQ, et al. Catecholamine-induced cardiomyopathy. Endocr Pract. 2008;14(9):1137-1149. Go to original source... Go to PubMed...
  8. de Miguel V, Arias A, Paissan A, et al. Catecholamine-induced myocarditis in pheochromocytoma. Circulation. 2014;129(12):1348-1349. Go to original source...
  9. Nölting S, Bechmann N, Taieb D, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43(2):199-239. Go to original source...
  10. Fliedner SMJ, Lehnert H, Pacak K. Metastatic paraganglioma. Semin Oncol. 2010;37(6):627-637. Go to original source...
  11. Vicha A, Musil Z, Pacak K. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):186-191. Go to original source...
  12. Eisenhofer G, Prejbisz A, Peitzsch M, et al. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clin Chem. 2018;64(11):1646-1656. Go to original source...
  13. Jochmanova I, Abcede AMT, Guerrero RJS, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol. 2020;146(4):1051-1063. Go to original source...
  14. Amar L, Pacak K, Steichen O, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435-444. Go to original source...
  15. Turkova H, Prodanov T, Maly M, et al. Charakteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an national institutes of health atudy. Endocr Pract. 2016;22(3):302-314. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.